Comparison of the effects of hypolipidaemic treatment on monocyte proinflammatory cytokine release in men and women with type 2 diabetes and atherogenic dyslipidaemia

Endokrynologia Polska

Volumn 66, Issue 3, 2015, Pages 224-230

  Krysiak, Robert ^a   Gdula Dymek, Anna ^a   Marek, Bogdan ^a,b   Okopień, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Third Provincial Hospital   (Poland)

Author keywords

Atherogenic dyslipidaemia; Cytokines; Fenofibrate; Monocytes; Sex; Simvastatin

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; FATTY ACID; FENOFIBRATE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; SIMVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; ANTILIPEMIC AGENT;

ADULT; AGE; AGED; ARTICLE; ATHEROGENESIS; ATHEROGENIC DYSLIPIDEMIA; BEDTIME DOSAGE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE EFFECTIVENESS; CYTOKINE RELEASE; DIABETIC PATIENT; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; SEX DIFFERENCE; WAIST CIRCUMFERENCE; ATHEROSCLEROSIS; BLOOD; COMPLICATION; DRUG EFFECTS; DYSLIPIDEMIAS; MIDDLE AGED; SECRETION (PROCESS);

ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CYTOKINES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; MONOCYTES; SEX FACTORS; SIMVASTATIN;

EID: 84937848242     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: 10.5603/EP.2015.0029     Document Type: Article

References (32)

1. Maas AH, Appelman YE. Gender differences in coronary heart disease. Neth Heart J 2010; 18: 598-602.
2. Roger VL, Go AS, Lloyd-Jones DM et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 2011; 123: e18-e209.
3. Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation 2011; 124: 2145-2154.
4. Athyros VG, Kakafika AI, Tziomalos K et al. Pleiotropic effects of statins - clinical evidence. Curr Pharm Des 2009; 15: 479-489.
5. Palaniswamy C, Selvaraj DR, Selvaraj T et al. Mechanisms underlying pleiotropic effects of statins. Am J Ther 2010; 17: 75-78.
6. Balakumar P, Rose M, Singh M. PPAR ligands: are they potential agents for cardiovascular disorders? Pharmacology 2007; 80: 1-10.
7. Keating GM, Croom KF. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 2007; 67: 121-153.
8. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
9. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207.
10. Manninen V, Tenkanen L, Koskinen et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85: 37-45.
11. Rubins HB, Robins SJ, Collins D et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002; 162: 2597-2604.
12. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-1574.
13. Wierzbicki AS. Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. Curr Opin Cardiol 2009; 24: 372-379.
14. Krysiak R, Gdula-Dymek A, Okopień B. Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia. Am J Cardiol 2011; 107: 1010-1018.e1.
15. Krysiak R, Okopień B. Different effects of simvastatin on ex vivo monocyte cytokine release in patients with hypercholesterolemia and impaired glucose tolerance. J Physiol Pharmacol 2010; 61: 725-732.
16. Krysiak R, Stachura-Kułach A, Okopień B. Metabolic and monocytesuppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances. Pharmacol Rep 2010; 62: 120-130.
17. Wirtz PH, von Känel R, Rohleder N et al. Monocyte proinflammatory cytokine release is higher and glucocorticoid sensitivity is lower in middle aged men than in women independent of cardiovascular risk factors. Heart 2004; 90: 853-858.
18. Bouman A, Schipper M, Heineman MJ et al. Gender difference in the non-specific and specific immune response in humans. Am J Reprod Immunol 2004; 52: 19-26
19. Cartier A, Côté M, Lemieux I et al. Sex differences in inflammatory markers: what is the contribution of visceral adiposity? Am J Clin Nutr 2009; 89: 1307-1314.
20. Jilma-Stohlawetz P, Homoncik M, Drucker C et al. Fy phenotype and gender determine plasma levels of monocyte chemotactic protein. Transfusion 2001; 41: 378-381.
21. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86: 515-581.
22. Kher N, Marsh JD. Pathobiology of atherosclerosis - a brief review. Semin Thromb Hemost 2004; 30: 665-672.
23. Hansson GK. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost 2009; 7 (Suppl. 1): 328-331.
24. Wilson HM, Barker RN, Erwig LP. Macrophages: promising targets for the treatment of atherosclerosis. Curr Vasc Pharmacol 2009; 7: 234-243.
25. Smith SC Jr. Current and future directions of cardiovascular risk prediction. Am J Cardiol 2006; 97: 28A-32A.
26. Capurso C, Capurso A. From excess adiposity to insulin resistance: the role of free fatty acids. Vascul Pharmacol 2012; 57: 91-97.
27. Keating GM, Omrod D. Micronised fenofibrate. An updated review of its clinical efficacy in the management of dyslipidaemia. Drugs 2002; 62: 1909-1944.
28. Martin G, Duez H, Blanquart C et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 2001; 107: 1423-1432.
29. Staels B, Maes M, Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med 2008; 5: 542-553.
30. Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett 2001; 507: 357-361.
31. Gonzales-Sanchez JL, Serrano-Rios M. Molecular basis of insulin action. Drug News Perspect 2007; 20: 527-531.
32. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev 2007; 65 (12 Pt 2): S253-S259.